Trial Profile

A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Guadecitabine (Primary)
Indications Small cell lung cancer
Focus Therapeutic Use

Most Recent Events

30 Apr 2025 Results assessing DNA methylation profiling of peripheral blood mononuclear cells from small-cell lung cancer patients from this study treated with hypomethylating agent plus carboplatin were presented at the 116th Annual Meeting of the American Association for Cancer Research
18 Dec 2023 Status changed from active, no longer recruiting to completed.
14 Feb 2022 Planned End Date changed from 2 Feb 2022 to 1 Feb 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com